In summary, the CNI tacrolimus appears have a greater impact on Tfh cells than other CD4+ T cell subsets making it of therapeutic interest in both transplantation and autoimmune disease, where increased cTfh cell frequency and an active GC reaction have been associated with autoantibody levels and end organ damage. Here, CD4 is linked to autoimmune disease.